Related Experiment Video

Updated: Jan 27, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status

Kazuhisa Nakashima1, Madoka Kimura2, Hiroaki Akamatsu3

  • 1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

Japanese Journal of Clinical Oncology
|March 29, 2019
PubMed
Abstract

Insights

Osimertinib shows good results for non-small cell lung cancer (NSCLC) patients with poor performance status (PS). This study found promising efficacy and safety in this patient group, suggesting a viable treatment option.

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Science

Background:

  • Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
  • It is effective for EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients with good performance status (PS).
  • Efficacy and safety in patients with poor PS were previously unknown.

Purpose of the Study:

  • To evaluate the efficacy and safety of osimertinib in NSCLC patients with poor PS.
  • To assess treatment outcomes in a patient population with limited prior data.

Main Methods:

  • Retrospective evaluation of 30 patients with EGFR T790M-positive NSCLC and ECOG PS scores of 2-4.
  • Patients received 80 mg of osimertinib once daily.
  • Data collected between March 2016 and February 2017.

Main Results:

  • Overall response rate was 53% (95% CI: 36-70%).
  • Performance status improvement rate was 63%.
  • Median progression-free survival was 8.2 months (95% CI: 4.3-13.2 months); no treatment-related deaths occurred.

Conclusions:

  • Osimertinib demonstrates promising efficacy in NSCLC patients with poor PS.
  • The drug shows acceptable safety in this population.
  • Osimertinib represents a potential treatment option for NSCLC patients with poor performance status.
Keywords:
EGFR T790M mutation-positivenon–small-cell lung cancerosimertinibpoor performance status

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

378
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.2K

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.7K
Mutations01:39

Mutations

Overview
94.5K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.2K
Position-effect Variegation02:32

Position-effect Variegation

In 1928, a German botanist Emil Heitz observed the moss nuclei with a DNA binding dye. He observed that while some chromatin regions decondense and spread out in the interphase nucleus, others do not. He termed them euchromatin and heterochromatin, respectively. He proposed that the heterochromatin regions reflect a functionally inactive state of the genome. It was later confirmed that heterochromatin is transcriptionally repressed, and euchromatin is transcriptionally active chromatin.
7.0K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
63.7K